文献速递慢阻肺

单吸入器三联疗法与LABA-ICS治疗COPD的真实世界安全性比较

Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD: Comparative Safety in Real-World Clinical Practice.
PubMed 文献 · Chest · 2024-10-24

基于英国CPRD数据库2017-2021年≥40岁COPD患者,倾向评分匹配后比较单吸入器三联疗法与LABA-ICS起始者的主要心血管不良事件(MACE)发生率。三联疗法组MACE发生率为11.3/100人年,LABA-ICS组为8.8/100人年,调整后HR为1.28(95%CI 1.05-1.55),增加主要见于治疗起始后前4个月(HR 1.41,95%CI 1.14-1.74),全因死亡HR为1.31(95%CI 1.06-1.62)。

要点

  • 真实世界中,COPD患者起始单吸入器三联疗法较LABA-ICS的MACE发生率升高。
  • MACE增加主要出现在治疗起始后前4个月内。
  • 全因死亡增加是MACE升高的主要驱动因素,心肌梗死和卒中住院风险无显著差异。

核心结论

  • 在真实世界COPD治疗中,起始单吸入器三联疗法的患者较LABA-ICS使用者MACE发生率升高。

研究设计与样本

  • 基于英国临床实践研究数据链(CPRD)2017-2021年≥40岁COPD患者的队列研究。
  • 在LAMA初治患者中,单吸入器三联疗法起始者与LABA-ICS使用者按时间条件倾向评分1:1匹配。
  • 共纳入10,255例三联疗法起始者和10,255例匹配的LABA-ICS使用者。
  • 主要结局为1年内MACE(心肌梗死或卒中住院或全因死亡)。

主要发现

  • 三联疗法组MACE发生率为11.3/100人年,LABA-ICS组为8.8/100人年。
  • 三联疗法相对LABA-ICS的MACE调整后HR为1.28(95%CI 1.05-1.55)。
  • MACE增加主要在前4个月(HR 1.41,95%CI 1.14-1.74)。
  • 全因死亡HR为1.31(95%CI 1.06-1.62)。
  • 急性心肌梗死住院HR为1.00(95%CI 0.56-1.79),卒中住院HR为1.06(95%CI 0.48-2.36)。

临床怎么用

  • 对LAMA初治的COPD患者起始单吸入器三联疗法时,应关注治疗早期(尤其前4个月)的心血管事件和死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent treatment guidelines for COPD have replaced the long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination with single-inhaler triple therapy that adds a long-acting muscarinic antagonist (LAMA). However, the corresponding trials reported numerically higher incidences of cardiovascular adverse events with triple therapy compared with LABA-ICS. RESEARCH QUESTION: Does single-inhaler triple therapy increase the incidence of major adverse cardiovascular events, compared with LABA-ICS, in a real-world clinical practice setting? STUDY DESIGN AND METHODS: We identified a cohort of patients with COPD aged ≥ 40 years treated during 2017-2021 from the UK's Clinical Practice Research Datalink. Among LAMA-naive patients, initiators of single-inhaler triple therapy were matched 1:1 to LABA-ICS users on time-conditional propensity scores. They were compared on the incidence of major adverse cardiovascular events (MACEs), defined as hospitalization for myocardial infarction or stroke, or all-cause-mortality, over 1 year. RESULTS: The cohort included 10,255 initiators of triple therapy and 10,255 matched users of LABA-ICS. The incidence rate of MACEs was 11.3 per 100 per year with triple therapy compared with 8.8 per 100 per year for LABA-ICS. The corresponding adjusted hazard ratio (HR) of MACEs with triple therapy was 1.28 (95% CI, 1.05-1.55), relative to LABA-ICS; however, the increase was mainly in the first 4 months (HR, 1.41; 95% CI, 1.14-1.74). The HR of all-cause death was 1.31 (95% CI, 1.06-1.62), whereas for acute myocardial infarction and stroke hospitalization it was 1.00 (95% CI, 0.56-1.79) and 1.06 (95% CI, 0.48-2.36), respectively, with triple therapy, relative to LABA-ICS. INTERPRETATION: In a real-world setting of COPD treatment, patients who initiated single-inhaler triple therapy had an increased incidence of MACEs compared with similar patients treated with an LABA-ICS inhaler. This small increase was due to the all-cause mortality component, occurring mainly in the first 4 months after treatment initiation.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Suissa S, Dell'Aniello S, Ernst P, et al. Single-Inhaler Triple vs Long-Acting Beta2-Agonist-Inhaled Corticosteroid Therapy for COPD: Comparative Safety in Real-World Clinical Practice. Chest. 2024. PMID: 39461554. doi:10.1016/j.chest.2024.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。